Pharmacologic considerations in the positioning of β-blockers in antihypertensive therapy

Current Hypertension Reports

Volumn 10, Issue 4, 2008, Pages 330-335

  Sica, Domenic A ^a   Black, Henry R ^b  

^a University Health System   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOXETINE; IRBESARTAN; LABETALOL; LOSARTAN; METHYLDOPA; METOPROLOL; NADOLOL; NEBIVOLOL; PAROXETINE; PROPAFENONE; PROPRANOLOL; QUINIDINE; RESERPINE; SOTALOL; THIAZIDE DIURETIC AGENT; TIMOLOL; BENZOPYRAN DERIVATIVE; CARBAZOLE DERIVATIVE; ETHANOLAMINE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ANTIHYPERTENSIVE THERAPY; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; DEPRESSION; DIABETES MELLITUS; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; HEART PROTECTION; HUMAN; HYPERTENSION; LETHARGY; MONOTHERAPY; NIGHTMARE; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SODIUM RETENTION; VASODILATATION; WATER RETENTION;

ADRENERGIC BETA-ANTAGONISTS; ATENOLOL; BENZOPYRANS; CARBAZOLES; ETHANOLAMINES; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; PROPANOLAMINES;

EID: 52449132961     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0061-7     Document Type: Review

References (45)

1. Bradley HA, Wiysonge CS, Volmink JA, et al.: How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006, 24:2131-2141.
2. Carlberg B, Samuelsson O, Lindholm LH: Atenolol in hypertension: is it a wise choice? Lancet 2004, 364:1684-1689.
3. Lindholm LH, Carlberg B, Samuelsson O: Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
4. Aursnes I, Osnes JB, Tvete IF, et al.: Does atenolol differ from other β-adrenergic blockers? BMC Clin Pharmacol 2007,7.4
5. Fouad FM, Slominski MJ, Tarazi RC, Gallagher JH: Alterations in left ventricular filling with beta-adrenergic blockade. Am J Cardiol 1983, 51:161-164.
6. Man in't Veld AJ, Van den Meiracker AH, Schalekamp MA: Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens 1988, 1:91-96.
7. Sica D, Frishman WH, Manowitz N: Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR, a new chronotherapeutic formulation. Heart Dis 2003, 5:176-181.
8. Frishman WH, Alwarshetty M: Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 2002, 41:505-516.
9. Vestal RE, Wood AJ, Branch RA, et al.: Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 1979, 26:8-15.
10. Dimsdale JE, Newton RP, Joist T: Neuropsychological side effects of beta-blockers. Arch Intern Med 1989, 149:514-525.
11. Dancey D, Wulffhart Z, McEwan P: Sotalol-induced torsades de pointes in patients with renal failure. Can J Cardiol 1997, 13:55-58.
12. Agarwal R: Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999, 55:1528-1535.
13. Cascorbi I: Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur J Clin Invest 2003, 33(Supp 2):17-22.
14. Cheymol G, Poirier JM, Carrupt PA, et al.: Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 1997, 43:563-570.
15. Galletti F, Fasano ML, Ferrara LA, et al.: Obesity and beta blockers: influence of body fat on their kinetics and cardiovascular effects. J Clin Pharmacol 1989 29:212-216.
16. Shand DG: Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. Drugs 1974, 7:39-47.
17. Prisant M. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory β1-blocker. J Clin Pharmacol 2008, 48:225-239.
18. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforscbung 2003, 53:814-822.
19. Sica DA: Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction. Am J Cardiol 2006, 98(7A):1L-4L.
20. Heel RC, Brogden RN, Speight TM, Avery GS: Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 1979, 17:425-460.
21. Pedersen ME, Cockcroft JR: The vasodilatory beta-blockers. Curr Hypertens Rep 2007, 9:269-277.
22. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: a cooperative study. JAMA 1977, 237:255-261.
23. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1980, 140:1280-1285.
24. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984, 144:1045-1057.
25. Moser M: Evolution of the treatment of hypertension from the 1940s to JNC V. Am J Hypertens 1997, 10:2S-8S.
26. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988, 148:1023-1038.
27. Moser M, Hebert PR: Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996, 27:1214-1218.
28. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 1993, 153:154-183.
29. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413-2446.
30. Fleisher LA, Beckman JA, Brown KA, et al.: ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy. Circulation 2006, 113:2662-2674.
31. Messerli FH, Grossman E, Goldbourt U: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998, 279:1903-1907.
32. Turakhia M, Tseng ZH: Sudden cardiac death: epidemiology, mechanisms, and therapy. Curr Prob Cardiol 2007, 32:501-546
33. Ishizaki T, Oyama Y, Suganuma T, et al.: A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics. Br J Clin Pharmacol 1983, 16:17-25.
34. Bangalore S, Messerli FH, Kostis JB, Pepine Cj: Cardiovascular protection using beta-blockers. J Am Coll Cardiol 2007, 50:563-572.
35. Kjeldsen SE, Dahlof B, Devereux RB, et al.: Effect of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002, 288:1491-1498.
36. Kolloch R, Legler UF, Champion A, et al.: Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (IN-VEST). Eur Heart J 2008, 29:1327-1334.
37. Brodde E: The pharmacology of bisoprolol. Rev Contemp Pharmacother 1997, 8:21-33.
38. Bang LE, Wiinberg N, Wachtell K, et al.: Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. Blood Press 2007, 16:392-397.
39. Blackburn DF, Lamb DA, Eurich DT, et al.: Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. J Hypertens 2007, 25:1499-1505.
40. Dhakam Z, Yasmin, McEniery CM, et al.: A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008, 26:351-356.
41. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
42. Devereux RB, Dahlöf B, Gerdts E, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456-1462.
43. Schiffrin EL, Park JB, Pu Q: Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothrlial function. J Hypertens 2002, 20:71-78.
44. Bangalore S, Parkar S, Grossman E, Messerli F: A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007, 100:1254-1262.
45. Leslie WS, Hankey CR, Lean ME: Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007, 100:395-404.